Possible immune adverse events as predictors of durable response to BRAF inhibitors in patients with BRAF V600–mutant metastatic melanoma

Erdmann "International trends in the incidence of malignant melanoma 1953-2008–are recent generations at higher or lower risk?" Int J Cancer (2013) 10.1002/ijc.27616

[2]

Cho "Epidemiology, staging (new system), and prognosis of cutaneous melanoma" Clin Plast Surg (2010) 10.1016/j.cps.2009.07.001

[3]

Ugurel "Survival of patients with advanced metastatic melanoma: the impact of novel therapies-update 2017" Eur J Cancer Oxf Engl 1990 (2017)

[4]

Long "Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma" J Clin Oncol Off J Am Soc Clin Oncol (2011) 10.1200/jco.2010.32.4327

[5]

Bauer "BRAF mutations in cutaneous melanoma are independently associated with age, anatomic site of the primary tumor, and the degree of solar elastosis at the primary tumor site" Pigment Cell Melanoma Res (2011) 10.1111/j.1755-148x.2011.00837.x

[6]

Long "Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study" Ann Oncol Off J Eur Soc Med Oncol (2017) 10.1093/annonc/mdx176

[7]

Grob Lancet Oncol (2015) 10.1016/s1470-2045(15)00087-x

[8]

Schachter "Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)" Lancet Lond Engl (2017) 10.1016/s0140-6736(17)31601-x

[9]

Wolchok "Overall survival with combined nivolumab and ipilimumab in advanced melanoma" N Engl J Med (2017) 10.1056/nejmoa1709684

[10]

Nagai "Optimal management of immune-related adverse events resulting from treatment with immune checkpoint inhibitors: a review and update" Int J Clin Oncol (2018) 10.1007/s10147-018-1259-6

[11]

Yuki "A case of pure red cell aplasia during nivolumab therapy for cardiac metastatic melanoma" Melanoma Res (2017) 10.1097/cmr.0000000000000392

[12]

Rupareliya "Acute inflammatory demyelinating polyneuroradiculopathy with ipilimumab in metastatic melanoma: a case report and review of literature" Cureus (2017)

[13]

Iglesias "Cancer immunotherapy-induced endocrinopathies: clinical behavior and therapeutic approach" Eur J Intern Med (2018) 10.1016/j.ejim.2017.08.019

[14]

Hua "Association of vitiligo with tumor response in patients with metastatic melanoma treated with Pembrolizumab" JAMA Dermatol (2016) 10.1001/jamadermatol.2015.2707

[15]

Lidar "Rheumatic manifestations among cancer patients treated with immune checkpoint inhibitors" Autoimmun Rev (2018) 10.1016/j.autrev.2018.01.003

[16]

Martini "Durable clinical benefit in metastatic renal cell carcinoma patients who discontinue PD-1/PD-l1 therapy for immune-related adverse events" Cancer Immunol Res (2018) 10.1158/2326-6066.cir-17-0220

[17]

Schadendorf "Efficacy and safety outcomes in patients with advanced melanoma who discontinued treatment with nivolumab and ipilimumab because of adverse events: a pooled analysis of randomized phase II and III trials" J Clin Oncol Off J Am Soc Clin Oncol (2017) 10.1200/jco.2017.73.2289

[18]

Snyder "Genetic basis for clinical response to CTLA-4 blockade in melanoma" N Engl J Med (2014) 10.1056/nejmoa1406498

[19]

PD-1 blockade induces responses by inhibiting adaptive immune resistance

Paul C. Tumeh, Christina L. Harview, Jennifer H. Yearley et al.

Nature 2014 10.1038/nature13954

[20]

Chapman "Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study" Ann Oncol Off J Eur Soc Med Oncol (2017) 10.1093/annonc/mdx339

[21]

Hauschild "Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial" Lancet Lond Engl (2012) 10.1016/s0140-6736(12)60868-x

[22]

Dummer "Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial" Lancet Oncol (2018)

[23]

Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trials

Georgina V Long, Jean-Jacques Grob, Paul Nathan et al.

The Lancet Oncology 2016 10.1016/s1470-2045(16)30578-2

[24]

McArthur "Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study" Lancet Oncol (2014) 10.1016/s1470-2045(14)70012-9

[25]

Long "Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma" N Engl J Med (2017) 10.1056/nejmoa1708539

[26]

Wilmott "Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma" Clin Cancer Res Off J Am Assoc Cancer Res (2012) 10.1158/1078-0432.ccr-11-2479

[27]

Sapkota "Vemurafenib enhances MHC induction in BRAFV600Ehomozygous melanoma cells" OncoImmunology (2013) 10.4161/onci.22890

[28]

Wongchenko "Association of programmed death ligand-1 (PD-L1) expression with treatment outcomes in patients with BRAF mutation-positive melanoma treated with vemurafenib or cobimetinib combined with vemurafenib" Pigment Cell Melanoma Res (2017)

[29]

Kfir-Elirachman "Regulation of CEACAM1 protein expression by the transcription factor ETS-1 in BRAF-mutant human metastatic melanoma cells" Neoplasia N Y N (2018) 10.1016/j.neo.2018.01.012

[30]

Tatli "Association of vitiligo and response in patients with metastatic malignant melanoma on temozolomide" Tumori (2015) 10.5301/tj.5000253

Metrics

30

Citations

30

References

Details

Published: Sep 01, 2018
Vol/Issue: 101
Pages: 229-235
License: View

Authors

Yael Steinberg-Silman

N

Nethanel Asher

R

Ronnie Shapira-Frommer

Sheba Medical Center 18 Ella Lemelbaum Institute for Immuno-Oncology, , Ramat Gan, Israel.

Lautenberg Center for General and Tumor Immunology, Hebrew University Hadassah Medical School , Jerusalem ,

Cite This Article

Guy Ben-Betzalel, Erez N. Baruch, Ben Boursi, et al. (2018). Possible immune adverse events as predictors of durable response to BRAF inhibitors in patients with BRAF V600–mutant metastatic melanoma. European Journal of Cancer, 101, 229-235. https://doi.org/10.1016/j.ejca.2018.06.030

Possible immune adverse events as predictors of durable response to BRAF inhibitors in patients with BRAF V600–mutant metastatic melanoma

You May Also Like